Causes of Elevated INR Without Bleeding
An elevated INR in a patient without bleeding most commonly results from vitamin K antagonist (VKA) therapy, but can also occur from liver disease, nutritional deficiencies, drug interactions, laboratory error, or hereditary factor deficiencies—and critically, the INR was designed and validated only for monitoring warfarin, not for predicting bleeding risk in non-VKA patients. 1
Understanding INR Validity and Limitations
The INR is only validated for patients on vitamin K antagonist therapy and does not reliably predict bleeding in other clinical contexts. 1 The test was standardized using plasma from stable warfarin patients, excluding those with liver disease, acute illness, or other coagulopathies. 1 There is no high-quality evidence that INR targets are appropriate for bleeding prediction in patients not receiving VKA therapy. 1
In non-VKA patients, the INR is a poor predictor of bleeding risk—a recent systematic review found weak or no association between INR and bleeding in 78 out of 79 studies assessed. 1
Primary Causes of Elevated INR
Vitamin K Antagonist (Warfarin) Therapy
Supratherapeutic dosing is the most common cause in anticoagulated patients, often triggered by medication changes (especially antibiotics), dietary vitamin K reduction, intercurrent illness, or non-adherence. 2, 3
Drug interactions are extremely common—warfarin interacts with numerous medications including antibiotics (especially fluoroquinolones, trimethoprim-sulfamethoxazole), NSAIDs, antifungals, and many others that either inhibit CYP2C9 metabolism or reduce vitamin K availability. 3
Dietary changes reducing vitamin K intake (decreased green vegetables) or increased alcohol consumption can elevate INR. 2, 3
Intercurrent illness such as fever, diarrhea, or reduced oral intake alters warfarin absorption and metabolism. 2
Chronic Liver Disease
Hepatic synthetic dysfunction reduces production of vitamin K-dependent clotting factors (II, VII, IX, X) and anticoagulant proteins (protein C, protein S), causing INR elevation. 1
The INR does not predict bleeding risk in liver disease—it was normalized against warfarin patients and does not account for the complex rebalanced hemostasis in cirrhosis. 1
The Model for End-Stage Liver Disease (MELD) score uses INR to assign disease severity, yet INR does not predict bleeding risk spontaneously or in connection with procedures in liver disease patients. 1
Elevated von Willebrand factor and low protein C in cirrhosis create a relatively hypercoagulable state despite elevated INR. 1
Vitamin K Deficiency
Nutritional deficiency from poor dietary intake, malabsorption (celiac disease, inflammatory bowel disease, chronic pancreatitis), or prolonged antibiotic use disrupting gut flora. 3
Prolonged NPO status or total parenteral nutrition without vitamin K supplementation can cause deficiency within 7-10 days. 3
Laboratory and Technical Factors
Falsely elevated INR can occur from improper specimen collection (underfilled tubes, clotted samples, prolonged tourniquet time), hemodialysis (strongest predictor with adjusted OR 9.60), or heparin contamination. 4
Lupus anticoagulant can prolong PT/INR without increasing bleeding risk—this is a critical pitfall where INR elevation does not reflect true anticoagulation. 4
Different thromboplastin reagents can produce variable INR results, particularly in non-warfarin patients, due to ISI calibration issues. 1
Hereditary and Acquired Factor Deficiencies
Isolated factor VII deficiency (hereditary or acquired) causes INR elevation because PT/INR measures the extrinsic pathway. 5
Factor IX deficiency can contribute to bleeding risk even when INR appears therapeutic—patients with lower factor IX levels have increased bleeding despite INR 2-3. 6
Factor levels decline at different rates with increasing INR: factor VII drops earliest, while factors II and IX remain near hemostatic levels until INR exceeds 2.5-3.0. 5
Disseminated Intravascular Coagulation (DIC)
- Consumptive coagulopathy depletes clotting factors and produces elevated INR, but the INR is a poor predictor of factor levels in DIC. 1
Massive Transfusion and Acute Trauma
- Dilutional coagulopathy and consumption of clotting factors elevate INR, but again, INR does not predict bleeding risk in these settings. 1
Critical Clinical Pitfalls
Do Not Treat Asymptomatic Elevated INR in Non-VKA Patients
There is no evidence that plasma transfusion reduces bleeding when administered to nonbleeding patients with incidentally abnormal INRs. 1
Plasma transfusion does not meaningfully change INR values below 1.5 and only minimally impacts values below 2.0, with no evidence for reduced bleeding at either target. 1
The practice of treating elevated INR with plasma in non-bleeding patients lacks biological plausibility and exposes patients to volumetric and immunologic risks. 1
INR Does Not Predict Procedural Bleeding Risk
In the perioperative setting, INR does not predict bleeding risk in patients with or without cirrhosis or on direct oral anticoagulants. 1
Randomized trials in periprocedural, critically ill, and liver disease patients find no reduction in bleeding when prophylactic plasma is given to correct INR values. 1
Age Amplifies Bleeding Risk
Advanced age (>65-75 years) markedly amplifies hemorrhagic risk at any INR level, independent of the absolute INR value. 2
Elderly patients require approximately 1 mg/day less warfarin than younger adults to achieve comparable INR prolongation. 2
Diagnostic Approach to Elevated INR Without Bleeding
Immediate Assessment
Confirm the patient is not on warfarin or other VKA—if they are, manage according to warfarin reversal guidelines based on INR level and bleeding risk factors. 2, 7
Repeat the INR to exclude laboratory error, especially if the value is markedly elevated or unexpected. 4
Review all medications for recent additions or changes, particularly antibiotics, NSAIDs, antifungals, or other drugs known to interact with vitamin K metabolism. 2, 3
Targeted History
Dietary assessment: recent changes in vitamin K intake (green vegetables, supplements), alcohol consumption, or prolonged NPO status. 2, 3
Gastrointestinal symptoms: diarrhea, steatorrhea, or malabsorption suggesting vitamin K deficiency. 3
Liver disease history: known cirrhosis, hepatitis, or signs of hepatic dysfunction. 1
Bleeding history: personal or family history of bleeding disorders suggesting hereditary factor deficiency. 6
Laboratory Evaluation
Liver function tests (AST, ALT, bilirubin, albumin) to assess hepatic synthetic function. 1
Individual factor levels (II, VII, IX, X) if INR remains unexplained—factor VII deficiency causes isolated INR elevation. 5
Mixing study if lupus anticoagulant is suspected (INR elevation without bleeding tendency). 4
Vitamin K level or empiric vitamin K trial (1-2 mg oral) with INR recheck in 24 hours. 2
Special Populations
Hemodialysis patients have the highest risk of falsely elevated INR (adjusted OR 9.60)—consider repeating sample or checking factor levels. 4
Liver disease patients require recognition that INR does not predict bleeding and should not trigger plasma transfusion. 1
Patients with mechanical heart valves on warfarin require careful assessment of thrombotic versus bleeding risk before any intervention. 2, 7
When to Intervene
VKA Patients Without Bleeding
INR 5.0-9.0: Withhold warfarin 1-2 doses; add oral vitamin K 1-2.5 mg only if high bleeding risk (age >65-75, prior bleeding, antiplatelet drugs, renal failure, alcohol use). 2
INR >10: Stop warfarin immediately and give oral vitamin K 2.5-5 mg; recheck INR in 24 hours. 2, 7
**Do not give vitamin K for INR <5.0** without bleeding—threshold for vitamin K in asymptomatic patients is >5.0. 2